James Investment Research Inc. Has $940,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR)

James Investment Research Inc. lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,665 shares of the biotechnology company’s stock after selling 144 shares during the quarter. James Investment Research Inc.’s holdings in United Therapeutics were worth $940,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in UTHR. World Investment Advisors LLC acquired a new stake in United Therapeutics during the 3rd quarter worth $139,206,000. FMR LLC raised its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the period. AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after purchasing an additional 161,751 shares during the period. Assetmark Inc. raised its stake in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,864 shares of company stock worth $44,516,965. Company insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Stock Performance

United Therapeutics stock opened at $370.58 on Monday. United Therapeutics Co. has a 52 week low of $211.61 and a 52 week high of $417.82. The stock has a market capitalization of $16.55 billion, a P/E ratio of 16.27, a PEG ratio of 0.92 and a beta of 0.57. The stock has a 50-day simple moving average of $361.93 and a 200 day simple moving average of $359.12.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.